Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0640

+6.7%

10:34 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mammon who wrote (11288)	5/17/2012 6:52:55 PM
From: boomertree2	3 Recommendations Read Replies (1) of 13111

Mammon, corporate insiders are potentially liable for material misstatements or omissions that would be material to an investors investment decision to buy or sell company stock. In the lawsuits against Dendreon, shareholders are claiming they purchased shares in reliance on management representations concerning the potential market for Provenge that turned out to have been grossly exaggerated. As a consequence, sales of the drug have been much lower than predicted, and DNDN stock prices have plummeted 400%. Shareholders that lost money allegedly on their detrimental reliance on management's market claims are suing management for their losses. As the PV-10 trials progressed and more results were reported, it was prudent for PVCT management to modify efficacy claims consistent with those results.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next